N-terminal telopeptide: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
<gallery> | |||
File:N-terminal telopeptide.svg|N-terminal telopeptide | |||
</gallery> | |||
Revision as of 01:28, 20 February 2025
N-terminal telopeptide (or NTX) is a biomarker used in medicine to measure the rate of bone turnover. It can be tested in the blood or urine to monitor osteoporosis and assess the effectiveness of osteoporosis treatment.
Overview
The N-terminal telopeptide is released during bone resorption and can be detected in the blood or urine. It is a useful marker for the process of bone turnover, providing information about the balance between bone resorption and formation. It can be used to diagnose osteoporosis, monitor the effectiveness of treatment, and predict future bone loss.
Clinical Use
NTX can be used to monitor the effectiveness of osteoporosis treatment. If the levels of NTX decrease, it suggests that the treatment is effective. It can also be used to predict the risk of fractures in postmenopausal women. High levels of NTX are associated with a higher risk of fractures.
Testing
NTX is measured in the urine or blood. The test is non-invasive and can be done at home. The results are usually available within a few days. The test is not affected by food intake and can be performed at any time of the day.
Limitations
While NTX is a useful marker of bone turnover, it is not a diagnostic test for osteoporosis. The diagnosis of osteoporosis is made based on bone mineral density measurements. Furthermore, NTX levels can be affected by other factors such as kidney function and vitamin D levels.


